(Hypertension. 1997;30:1097-1104.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Pathology, University of Iowa College of Medicine and Cardiovascular Center, Iowa City.
Correspondence to Gary L. Baumbach, MD, Department of Pathology, 105 Medical Laboratories, University of Iowa College of Medicine, Iowa City, IA 52242. E-mail g-baumbach{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Key Words: L-NAME hypertrophy nitric oxide remodeling
| Introduction |
|---|
|
|
|---|
Several determinants appear to contribute to alterations in vascular structure during chronic hypertension. Determinants implicated in hypertrophy include increases in arterial pressure,3 in particular pulse pressure,4 5 6 sympathetic nerves,7 8 the renin-angiotensin system,9 10 and the endothelium-derived factor endothelin.11 12 Determinants that may contribute to remodeling include genetic factors2 and the renin-angiotensin system.4 In contrast to their apparent contributions to hypertrophy, increases in pulse pressure,5 sympathetic nerves,7 and endothelin11 apparently do not play a role in remodeling. Thus, determinants of hypertrophy and remodeling apparently differ.
Another determinant that may contribute to alterations in vascular structure during chronic hypertension is the endothelium-derived relaxing factor NO. This suggestion is based on the following observations. First, inhibitors of NO synthase induce hypertension in rats.13 14 15 In addition, topical application of NO synthase inhibitors in vivo produces constriction of cerebral blood vessels in Sprague-Dawley rats.16 17 These findings indicate that production and release of NO by vascular endothelium may contribute to the regulation of resting vascular tone both systemically and in the brain. Second, blood pressure in Dahl salt-sensitive rats on a high salt diet is normalized by treatment with L-arginine, the substrate for NO production.18 Thus, in at least one model of chronic hypertension, reduced availability or release of NO may contribute to the maintenance of chronically elevated arterial pressure. Finally, it has been observed that vasodilator drugs that generate NO inhibit mitogenesis and proliferation of vascular smooth muscle in culture.19 This observation suggests that in addition to regulation of resting vascular resistance, NO also may contribute to regulation of vascular structure.
The first goal of this study was to examine the effects of chronic treatment with the NO synthase inhibitor L-NAME on wall mass of cerebral arterioles in rats. Because treatment with L-NAME causes hypertension, we placed a clip on one carotid artery in some rats to normalize cerebral arteriolar pulse pressure and thus separate the effects of increased pressure per se from nonpressor effects of L-NAME. Our hypothesis was that chronic hypertension induced by inhibition of NO production may produce cerebral vascular hypertrophy independently of increases in cerebral arteriolar pressure. The second goal was to determine whether treatment with L-NAME results in increases in cerebral arteriolar distensibility. In previous studies, we found that hypertrophy is associated with increases in distensibility of cerebral arterioles in SHR and renal hypertensive rats.2 Thus, it seemed likely that L-NAMEinduced hypertension is accompanied by increases in arteriolar distensibility. The third goal was to determine whether L-NAME results in remodeling of cerebral arterioles. Based on previous findings that cerebral arterioles undergo remodeling in SHR but not in Sprague-Dawley rats with renal hypertension, we suggested that genetic factors may play a role in remodeling.2 It seemed plausible, therefore, that treatment with L-NAME would not result in remodeling of cerebral arterioles in Sprague-Dawley rats.
| Methods |
|---|
|
|
|---|
To examine the effects of inhibition of NO synthase on cerebral
arterioles, a group of rats was treated with L-NAME (100 mg/L)
in the drinking water beginning at 4 weeks of age. Rats that drank tap
water served as controls. Water intake in the L-NAMEtreated groups
decreased from
200 mL/kg per day at the beginning of treatment to
100 mL/kg per day at the end. Thus, intake of L-NAME during the
treatment period decreased from
20 mg/kg per day to
10
mg/kg per day.
To determine whether the effects of L-NAME on cerebral arterioles resulted from increases in arterial pressure, a second group of rats underwent unilateral carotid clipping before treatment with L-NAME was begun. Rats were anesthetized with sodium pentobarbital (2.5 mg/100 g body wt, IP), and a clip was placed on the left common carotid artery. Clips with a gap size of 0.30 mm were made from 2-mm strips of silver sheet. The right carotid artery was exposed but not clipped. Because we could not exclude damage to sympathetic nerves caused by the carotid clip, the superior cervical ganglia were removed on both sides. Rats that underwent exposure of both carotid arteries and removal of both superior cervical ganglia and drank tap water served as controls for L-NAMEclipped rats.
After about 3 months of treatment, we examined the mechanics of cerebral arterioles. Animals were weighed and anesthetized with sodium pentobarbital (5 mg/100 g body wt, IP), intubated, and mechanically ventilated with room air and supplemental oxygen. Paralysis of skeletal muscle was obtained with gallamine triethiodide (20 mg/kg IV). Because the animals were paralyzed, we evaluated them frequently for adequacy of anesthesia. Additional anesthesia (1.7 mg/100 g body wt, IV) was administered when pressure to a paw evoked a change in blood pressure or heart rate.
A catheter was inserted into a femoral vein for injection of drugs and fluids. A catheter was inserted into a femoral artery to record systemic arterial pressure and obtain blood samples for measurement of arterial blood gases, and a catheter was inserted into the other femoral artery to withdraw blood to produce hypotension.
Measurement of Cerebral Arteriolar Pressure and Diameter
We measured pressure and diameter in first-order arterioles on
the cerebrum20 through an open skull
preparation.21 The head was placed in an adjustable head
holder, and a 1-cm incision was made in the skin to expose the skull.
The skin edges were retracted with sutures, and ports were placed for
inflow and outflow of artificial CSF. A craniotomy was
made over the left parietal cortex, and the dura was incised to expose
cerebral vessels. In rats with unilateral carotid clipping, a dam of
acrylic was constructed along the exposed portion of the superior
sagittal suture, and craniotomies were made over the parietal cortex of
the left and right cerebral hemispheres.5 The exposed
brain was continuously suffused with artificial CSF, warmed to 37°C
to 38°C, and equilibrated with a gas mixture of 5%
CO2/95% N2. The composition of the CSF was
(mmol/L): KCl 3.0, MgCl2 0.6, CaCl2 1.5,
NaCl 131.9, NaHCO3 24.6, urea 6.7, dextrose
3.7.21
Systolic, diastolic, mean, and pulse pressures were measured continuously in cerebral arterioles with a micropipette connected to a servo-null pressure-measuring device (model 5, Instrumentation for Physiology and Medicine, Inc). Pipettes were sharpened to a beveled tip of 3 to 5 µm in diameter, filled with 1.5 mol/L sodium chloride, and inserted into the lumen of a cerebral arteriole with a micromanipulator. The presence of the pipette tip in the vessel had no discernible effect on the diameter of cerebral arterioles.
Arterioles were monitored through a microscope connected to a closed-circuit video system with a final magnification of x356. Images of arterioles were digitized using a video frame grabber installed in a Macintosh computer (Quadra 900, Apple Computer). Arteriolar diameter was measured from the digitized images using image-analysis software (NIH Image, National Institutes of Health, Research Services Branch, NIMH). The precision of this system is 0.4 to 0.6 µm.
Experimental Protocol
Approximately 20 to 30 minutes after surgery, measurements of
cerebral arterioles were obtained under baseline conditions. Vascular
smooth muscle was then deactivated by suffusion of cerebral
vessels with artificial CSF containing EDTA (67 mmol/L),
which produces complete deactivation of smooth muscle in cerebral
arterioles.21 Pressure-diameter relationships were
obtained in deactivated cerebral arterioles between cerebral
arteriolar pressures of 50 and 10 mm Hg in the hypertensive rats
and 40 and 10 mm Hg in the normotensive rats. Hemorrhage
was used to reduce cerebral arteriolar pressure in decrements of
10 mm Hg at pressures down to 20 mm Hg of cerebral
arteriolar pressure and decrements of 5 mm Hg at pressures
between 20 and 10 mm Hg. After each pressure step, arteriolar
diameter achieved a steady state within 15 seconds. Inner diameter was
measured
30 seconds later. Maximally dilated arterioles were fixed
at physiological pressure in vivo by suffusion of
vessels with glutaraldehyde fixative (0.0225
glutaraldehyde in 0.10 mol/L cacodylate buffer)
while cerebral arteriolar pressure were maintained at baseline levels.
Arterioles were considered to be adequately fixed when blood flow
through the arteriole ceased. After the animal was killed by an
injection of potassium chloride, the arteriolar segment used for
pressure-diameter measurements was removed, processed for electron
microscopy, and embedded in Spurr's low-viscosity resin while
cross-sectional orientation was maintained.
Cross-sectional area of the arteriolar wall was determined histologically from 1-µm sections using a light microscope interfaced with the video image analyzing system described above. Luminal and total (lumen plus vessel wall) cross-sectional areas of the arteriole were measured by tracing the inner and outer edges of the vessel wall. Cross-sectional area of the vessel wall was calculated by subtracting luminal cross-sectional area from total cross-sectional area.
Calculation of Mechanical Characteristics
The assumptions on which we based calculations of
circumferential stress, circumferential strain, and tangential elastic
modulus have been described in detail previously.5 21
Circumferential stress (
) was calculated from cerebral arteriolar
pressure (P), inner diameter of cerebral arterioles (Di),
and wall thickness (WT):
=(PxDi)/(2WT). Cerebral
arteriolar pressure was converted from millimeters of mercury to
newtons per square meter (1 mm Hg=1.334x102
N/m2). Wall thickness was calculated from the
cross-sectional area of the vessel wall (CSA) and inner cerebral
arteriolar diameter:
WT=[(4CSA/
+Di2)1/2Di]/2.
External diameter of cerebral arterioles (De) was
calculated as De=Di+2WT.
Histological determinations of cross-sectional area
were used in all calculations of wall thickness and circumferential
stress. Circumferential strain (
) was calculated as
=(DiDo)/Do, where
Do is original diameter. We defined original diameter as
the diameter at 10 mm Hg pressure.
To obtain tangential elastic modulus, the stress-strain data from each
animal were fitted to an exponential curve (y=aebx) using
least-squares analysis:
=
oeß
, where
o is stress at original diameter and ß is a constant
that is related to the rate of increase of the stress-strain curve.
Tangential elastic modulus (ET) was calculated at several
different values of stress from the derivative of the exponential
curve:
ET=d
/d
=ß
oeß
.
Determination of Wall Composition
Volume density of smooth muscle, elastin, collagen, basement
membrane associated with endothelium and smooth muscle,
and endothelium was quantitated from electron
micrographs of the vessel wall using a method we have described
previously.22 Ultrathin sections of the arteriolar wall
were cut on an ultramicrotome and stained with phosphotungstic acid
(0.0025). Electron micrographs were taken at a standard magnification
of x9000 and enlarged photographically by a factor of 3 for a final
magnification of x27 000. To ensure uniform sampling, the vessel wall
was divided into four quadrants of equal size. At least two electron
micrographs were taken randomly in each quadrant for a total of 10
electron micrographs per vessel.
A standard point-counting grid (double square lattice test system D16)23 was used to count the number of points contained within profiles of smooth muscle, elastin, collagen, basement membrane, and endothelium. Volume density (VV) of each component was calculated from the number of points in each component (Pa) and the total number of points contained within the vessel wall (PT): VV=Pa/PT. Cross-sectional area of individual wall components (CSAC) was calculated from VV of each component and total cross-sectional area (CSAT) of the wall measured histologically: CSAC=CSATxVV.
Assay of NO Synthase Activity by
L-[14C]Citrulline Production
Portions of cerebellum from untreated and L-NAMEtreated
Sprague-Dawley rats were frozen under liquid nitrogen and stored at
-70°C. Activity of NO synthase was determined as the rate of
conversion of L-[14C]arginine (DuPont NEN) to
L-[14C]citrulline following a method
previously described.24 Brain tissue samples were
homogenized in 20 vol (wt/vol) of ice-cold buffer [50
mmol/L tris(hydroxymethyl)aminomethane, 2
mmol/L EDTA, pH 7.4] and centrifuged at
10 000g for 15 minutes at 4°C. Enzyme activity was
assayed at 20°C in duplicate using the supernatant. The reaction was
initiated by adding 25 µL of brain supernatant to 100 µL of a
mixture containing 3 µmol/L
L-[14C]arginine, 1 mmol/L NADPH,
and 1 mmol/L CaCl2. The reaction was terminated
after 15 minutes by adding 1.8 mL of stop buffer [30
mmol/L
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid and 3 mmol/L EDTA, pH 5.5].
Samples were applied to a 0.5-mL Dowex resin column (Sigma No. 50X-400, Na+ form) to remove L-[14C]arginine. The columns were then washed with 1 mL of water, and L-[14C]citrulline was quantified in the flow-through fraction using a scintillation counter. Enzyme activity is expressed as picomoles per milligram protein per minute. The concentration of L-[14C]citrulline was calculated after subtracting the blank value, which represents nonspecific radioactivity in the absence of enzyme activity. To determine whether the measured citrulline production was due to activity of constitutive NO synthase (calcium-dependent NO synthase), parallel samples were processed in the absence of calcium and in the presence of a potent inhibitor of activity of NO synthase (L-NAME, 1 mmol/L). Protein concentrations of the samples were measured using the Bradford assay.
Statistical Analysis
ANOVA was used to compare systemic mean pressure, arteriolar
pressures, diameters, cross-sectional area of the vessel wall,
cross-sectional area and volume density of individual components,
ratios of nondistensible to distensible components, and slope of
tangential elastic modulus versus stress. Probability values were
calculated using Student's t test. Statistics were
determined using JMP statistics software (SAS Institute Inc) on a
Macintosh computer.
| Results |
|---|
|
|
|---|
Systemic mean arterial pressure and cerebral arteriolar
systolic, diastolic, mean, and pulse pressures were
significantly greater in L-NAMEtreated rats than in untreated rats
(Table 1
). Diameter before deactivation
with EDTA was not significantly different in cerebral arterioles of
rats treated with L-NAME than in untreated rats (Table 1
). During
deactivation with EDTA, internal and external diameters and
cross-sectional area of the vessel wall were greater in cerebral
arterioles in rats treated with L-NAME than in cerebral arterioles in
untreated rats (Table 1
). Thus, during L-NAMEinduced hypertension
in rats, cerebral arterioles underwent hypertrophy of the
vessel wall.
|
Although carotid clipping in L-NAMEtreated rats significantly reduced
both mean and pulse pressure in cerebral arterioles, it was more
effective in reducing pulse pressure than mean pressure (Table 2
). Pulse pressure was similar in clipped
cerebral arterioles in L-NAMEtreated rats and cerebral arterioles in
untreated rats. In contrast, mean pressure was significantly higher in
clipped arterioles in L-NAMEtreated rats than in arterioles in
untreated rats (Table 2
). Active and passive diameters and
cross-sectional area of the vessel wall were not significantly
different in sham and clipped cerebral arterioles of L-NAMEtreated
rats (Table 2
). Thus, carotid clipping in L-NAMEtreated rats did not
prevent hypertrophy of cerebral arterioles, even though it
normalized arteriolar pulse pressure.
|
Vascular Mechanics
Internal diameter in cerebral arterioles during maximal
dilatation was larger in L-NAMEtreated rats than in untreated rats at
all levels of arteriolar pressure between 10 and 40 mm Hg (Fig 1
, left panel). The stress-strain curve in
cerebral arterioles in L-NAMEtreated rats was similar to the curve in
cerebral arterioles in control rats (Fig 1
, right panel). In addition,
the slope of tangential elastic modulus versus stress was not
significantly different in L-NAMEtreated rats and untreated rats
(5.4±0.4 versus 5.1±0.5). These findings suggest that L-NAMEinduced
hypertension was not accompanied by alterations in passive
distensibility of cerebral arterioles, despite hypertrophy
of the vessel wall.
|
Unilateral carotid clipping had no effect on the relationship between
pressure and internal diameter (Fig 2
, left
panel) or on the stress-strain curve (Fig 2
, right panel) and the slope of tangential elastic modulus versus
stress (4.7±0.3 versus 5.1±0.4 for the sham arterioles) in cerebral
arterioles of L-NAMEtreated rats. These findings suggest that
increases in cerebral arteriolar diameter in L-NAMEtreated rats
occurred independently of increases in cerebral arteriolar pulse
pressure.
|
Composition
Cross-sectional areas of smooth muscle, elastin, and basement
membrane associated with smooth muscle and endothelium
were significantly greater in rats treated with L-NAME than in
untreated rats (Table 3
). Cross-sectional
area of collagen was not significantly increased, whereas
cross-sectional area of endothelium was similar in rats
treated with L-NAME compared with untreated rats (Table 3
).
|
To relate composition of the vessel wall to passive distensibility, we
calculated the ratio of nondistensible to distensible components in the
arteriolar wall, as discussed previously.7 22 When
basement membrane (BaseM) was combined with collagen (C), and when
smooth muscle (SM) and endothelium (Endo) were combined
with elastin (E), the ratio of nondistensible to distensible components
([C+BaseM]/[E+SM+Endo]) was similar in untreated and treated rats
(Table 3
). Thus, when all of the major components of the arteriolar
wall were taken into account, hypertrophy of cerebral
arterioles in rats with L-NAMEinduced hypertension was not
accompanied by a modification in the proportion of the components of
the arteriolar wall.
NO Synthase Activity
Treatment with L-NAME for 3 months decreased NO synthase activity
in cerebellum of Sprague-Dawley rats, as expressed by the rate of
conversion of L-[14C]arginine to
L-[14C]citrulline (9.28±0.72 versus
45.10±3.95 pmol/mg per minute, P<.05). This finding
indicates that chronic treatment with L-NAME was sufficient to inhibit
NO synthase activity in the brain, and thus suggests that availability
of NO was diminished in cerebral blood vessels of L-NAMEtreated
rats.
| Discussion |
|---|
|
|
|---|
Hypertrophy
Cerebral arterioles undergo hypertrophy in several
models of experimental hypertension including SHRSP, SHR, and renal
hypertension.2 21 Determinants that may contribute to
cerebral vascular hypertrophy during chronic hypertension
include increases in pressure,3 25 neurohumoral
factors,7 8 9 10 genetic factors,26 27 and
endothelial factors, such as
endothelin.11 12
Another endothelium-derived product that may
contribute to regulation of vessel growth is NO. Consideration for this
possibility first emerged with the finding that NO suppresses
mitogenesis and proliferation of vascular smooth muscle cells in tissue
culture.19 On the other hand, an important role for NO in
vascular growth has not been supported by more recent studies in which
NO synthase inhibitors were used to suppress
production of NO in living animals. Dunn and
Gardiner28 found that treatment with L-NAME produced no
change in cross-sectional area of the vessel wall in mesenteric
resistance arteries in Brattleboro rats. Although Schiffrin and
colleagues29 30 found an increase in cross-sectional area
of the vessel wall in mesenteric resistance arteries in L-NAMEtreated
rats, the increase was smaller in magnitude (
CSA of
7% to 10%)
than often found by other investigators in other models of hypertension
that have levels of arterial pressure similar to those in
rats treated with L-NAME, such as SHR31 (
CSA of
70%) and renal hypertensive rats (
CSA of
40%).32
We found in this study that treatment of rats with L-NAME not only
resulted in an increase in cross-sectional area of the vessel wall in
cerebral arterioles, but the magnitude was greater (
CSA of
50%
to 80%) than in small mesenteric arteries28 29 30 and was
similar to, or greater than, increases found in cerebral arterioles in
other models of hypertension that have similar increases in
arterial pressure, including SHR2 (
CSA of
58%), SHRSP21 (
CSA of
30%), and renal
hypertensive rats2 (
CSA of
43%). Thus, in contrast
to previous studies,28 29 30 the findings in this study
suggest that chronic hypertension induced by inhibition of NO synthase
may produce substantial hypertrophy in the cerebral
circulation. Furthermore, the findings also support the concept that NO
may play an important role in the regulation of vascular growth.
We have considered three possibilities to account for the discrepancy between the magnitude of L-NAMEinduced hypertrophy found in this study and previous studies.28 29 30 First, L-NAME may inhibit growth of vascular smooth muscle directly when given in higher doses,33 which in turn would tend to negate any vascular growth that might otherwise occur as a consequence of reduced availability of NO and its antiproliferative effects. The dose of L-NAME used to induce hypertension was substantially higher in previous studies28 29 30 (50 to 100 mg/kg per day) than in this study (10 mg/kg per day). It is possible, therefore, that if a higher dose of L-NAME had been used in this study, less hypertrophy might have resulted in cerebral arterioles.
Another possibility is that the effects of L-NAMEinduced hypertension on vascular growth are time-dependent. In this study, rats were treated with L-NAME for 12 weeks as opposed to 2 to 4 weeks in previous studies.28 29 30 If the degree of vascular hypertrophy increases as a function of exposure to L-NAME and hypertension, it would not be surprising to find a greater magnitude of vascular hypertrophy in this study than in studies in which duration of treatment was shorter.
A third possibility is that the effects of L-NAMEinduced hypertension
on vascular growth may depend on vessel size and region. We examined
cerebral arterioles with an average inner diameter of
90 µm
(maximally dilated), whereas investigators in previous studies examined
mesenteric resistance arteries with an average inner diameter of
220 µm.28 29 30
An important consideration in this study is whether hypertrophy of cerebral arterioles in L-NAMEtreated rats resulted directly from increases in arteriolar pressure per se rather than a nonpressor effect of L-NAME. To test this possibility, we examined the effects of unilateral carotid clipping, which we previously found to normalize pulse pressure and prevent hypertrophy in cerebral arterioles of SHRSP.5 In this study, carotid clipping did not prevent hypertrophy of cerebral arterioles in L-NAMEtreated rats, even though increases in arteriolar pulse pressure were prevented. On the other hand, carotid clipping failed to normalize systolic and mean pressures in cerebral arterioles. Thus, we cannot rule out the possibility that hypertrophy in cerebral arterioles of L-NAMEtreated rats was the result of increases in systolic or mean pressure. There are two reasons to consider this possibility less likely, however. First, carotid clipping prevents cerebral arteriolar hypertrophy in SHRSP, even though clipping only partially attenuates increases in arteriolar systolic and mean pressures.5 Second, arteriovenous fistulae in rats increases pulse pressure, but not mean pressure, in cerebral arterioles and results in hypertrophy of the arteriolar wall.34
Another factor that may have contributed to hypertrophy of cerebral arterioles in rats treated with L-NAME is an interaction with the renin-angiotensin system. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prevent or attenuate increases in blood pressure in L-NAMEtreated rats.35 36 37 At the same time, however, treatment with L-NAME apparently does not increase plasma angiotensin II levels35 36 37 and either has no effect on plasma renin activity35 36 or results in increases in plasma renin only after 4 to 6 weeks of treatment.37 These findings suggest an interaction between angiotensin II AT1 receptors and NO synthase inhibition. In this study, therefore, it is possible that treatment of rats with L-NAME may have resulted in activation of AT1 receptors, which in turn may have stimulated hypertrophy of cerebral arterioles.
Finally, it has been suggested that NO may play a role in the regulation of endothelin-1 gene expression in blood vessels.38 This suggestion is based on the finding that treatment with L-NAME results in increases in severity of hypertrophy in aorta and large mesenteric arteries in SHR together with increases in endothelin-1 mRNA in the vessel wall.38 In contrast, neither severity of hypertrophy nor endothelin-1 mRNA is increased in small mesenteric resistance arteries of SHR during treatment with L-NAME.39 These findings suggest that L-NAME stimulates production of endothelin-1 in large, but not small, arteries and thus results in additional hypertrophy only in large arteries as a consequence of the trophic effects of endothelin-1.40 41 On the basis of this assumption, one might conclude that in this study, endothelin-1 did not contribute to hypertrophy of cerebral arterioles in L-NAMEtreated rats. On the other hand, we are unaware of any evidence to indicate that L-NAME does not increase endothelin-1 mRNA in cerebral arterioles. Thus, one cannot rule out absolutely a role for endothelin-1 in the development of cerebral arteriolar hypertrophy during treatment with L-NAME.
Mechanics and Composition
Delacrétaz and colleagues42 observed that
hypertension caused by chronic inhibition of NO synthesis in
Wistar-Kyoto rats was not associated with altered distensibility in
carotid artery, in contrast to SHR in which distensibility of carotid
artery was increased. We found in this study that L-NAMEinduced
hypertension did not alter passive distensibility of cerebral
arterioles in rats. These findings suggest that L-NAMEinduced
hypertension does not alter passive distensibility in large or small
cerebral arteries.
We have proposed previously that increases in distensibility that accompany hypertrophy of cerebral arterioles in SHRSP, SHR, and rats with one-kidney, one clip renal hypertension may be due to a reduction in the proportion of stiff (collagen and basement membrane) to compliant (smooth muscle, elastin, and endothelium) components in cerebral arterioles.2 22 If proportional composition influences vascular distensibility, one might anticipate that an absence of altered vascular distensibility during hypertension would be accompanied by no change in proportional composition of the vessel wall. The findings in this study appear to support this concept. The ratio of nondistensible to distensible components, as well as distensibility, was not altered in cerebral arterioles of L-NAMEtreated rats.
Remodeling
Cerebral arterioles in SHRSP1 and
SHR,2 but not in renal hypertensive rats,2
undergo remodeling of the vessel wall with a reduction in external
diameter. Based on these findings, we suggested that genetic factors
may play a role in the remodeling of cerebral arterioles with a
reduction in external diameter during chronic
hypertension.2 The findings of the present study
provide additional support for the possibility that genetic factors,
present in SHRSP and SHR but not in Sprague-Dawley rats, contribute
to the remodeling of cerebral arterioles during chronic hypertension.
In this study, we found that treatment of Sprague-Dawley rats with
L-NAME does not result in a reduction of external diameter in cerebral
arterioles. Instead, we found that L-NAMEinduced hypertension was
accompanied by an increase in external diameter. Increases in external
diameter have been described previously in atherosclerotic arteries in
monkeys43 and humans.44 The factors
responsible for increases in external diameter of large arteries in
atherosclerosis and cerebral arterioles in
L-NAMEinduced hypertension are not yet well defined. Nonetheless, it
is tempting to speculate that reductions in availability of NO may play
a role in both cases. In atherosclerosis, for example,
availability of NO in large arteries may be reduced by increased
destruction of NO, perhaps by release of oxygen radicals from
leukocytes in the arterial wall.45
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received October 16, 1996; first decision December 10, 1996; accepted April 23, 1997.
| References |
|---|
|
|
|---|
2.
Baumbach GL, Hadju MA. Mechanics and
composition of cerebral arterioles in renal and spontaneously
hypertensive rats. Hypertension. 1993;21:816-826.
3. Folkow B, Gurevich M, Hallbäck M, Lundgren Y, Weiss L. The hemodynamic consequences of regional hypotension in spontaneously hypertensive and normotensive rats. Acta Physiol Scand. 1971;83:532-541.[Medline] [Order article via Infotrieve]
4.
Hadju MA, Heistad DD, Baumbach GL. Effects of
antihypertensive therapy on mechanics of cerebral arterioles in
rats. Hypertension. 1991;17:308-316.
5.
Baumbach GL, Siems JE, Heistad DD. Effects of
local reduction in pressure on distensibility and composition of
cerebral arterioles. Circ Res. 1991;68:338-351.
6.
Christensen KL. Reducing pulse pressure in
hypertension may normalize small artery structure.
Hypertension. 1991;18:722-727.
7.
Baumbach GL, Heistad DD, Siems JE. Effect of
sympathetic nerves on composition and distensibility of cerebral
arterioles in rats. J Physiol (Lond). 1989;416:123-140.
8.
Lee RMKW, Triggle CR, Cheung D, Coughlin M.
Structural and functional consequence of neonatal
sympathectomy on the blood vessels of spontaneously
hypertensive rats. Hypertension. 1987;10:328-338.
9. Fischli W, Hefti F, Clozel JP. Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats. Br J Clin Pharmacol. 1989;27:151S-158S.
10.
Geisterfer AAT, Peach MJ, Owens GK.
Angiotensin II induces hypertrophy, not
hyperplasia, of cultured rat aortic smooth muscle cells.
Circ Res. 1988;62:749-756.
11.
Chillon JM, Heistad DD, Baumbach GL. Effects of
endothelin receptor inhibition on cerebral arterioles in hypertensive
rats. Hypertension. 1996;27:794-798.
12.
Li JS, Larivière R, Schiffrin EL. Effect
of a nonselective endothelin antagonist on vascular
remodeling in deoxycorticosterone acetate-salt hypertensive
rats. Hypertension. 1994;24:183-188.
13.
Rees DD, Palmer RMJ, Moncada S. Role of
endothelium-derived nitric oxide in the regulation of
blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-3378.
14.
Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada
S. Control of regional blood flow by
endothelium-derived nitric oxide.
Hypertension. 1990;15:486-492.
15.
Tolins JP, Palmer RMJ, Moncada S, Raij L. Role
of endothelium-derived relaxing factor in regulation of
renal hemodynamic responses. Am J
Physiol. 1990;258:H655-H662.
16.
Faraci FM. Role of
endothelium-derived relaxing factor in cerebral
circulation: large arteries vs. microcirculation. Am
J Physiol. 1991;261:H1038-H1042.
17.
Faraci FM. Role of nitric oxide in regulation of
basilar artery tone in vivo. Am J Physiol. 1990;259:H1216-H1221.
18. Chen PY, Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991;88:1559-1567.
19. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
20.
Harper SL, Bohlen HG. Microvascular adaptation
in the cerebral cortex of adult spontaneously hypertensive
rats. Hypertension. 1984;6:408-419.
21.
Baumbach GL, Dobrin PB, Hart MN, Heistad DD.
Mechanics of cerebral arterioles in hypertensive rats.
Circ Res. 1988;62:56-64.
22. Baumbach GL, Walmsley JG, Hart MN. Composition and mechanics of cerebral arterioles in hypertensive rats. Am J Pathol. 1988;133:464-471.[Abstract]
23. Weibel ER. Stereological Methods: practical Methods for Biological Morphometry. New York: Academic Press; 1979.
24.
Faraci FM, Brian JEJ, Heistad DD. Response of
cerebral blood vessels to an endogenous
inhibitor of nitric oxide synthase. Am J
Physiol. 1995;269:H1522-H1527.
25. Weiss L, Hallbäck M. Time course and extent of structural vascular adaptation to regional hypotension in adult spontaneously hypertensive rats (SHR). Acta Physiol Scand. 1974;91:365-373.[Medline] [Order article via Infotrieve]
26. Lee RMKW. Vascular changes at the prehypertensive phase in the mesenteric arteries from spontaneously hypertensive rats. Blood Vessels. 1985;22:105-126.[Medline] [Order article via Infotrieve]
27.
Eccleston-Joyner CA, Gray SD.
Arterial hypertrophy in the fetal and neonatal
spontaneously hypertensive rats. Hypertension. 1988;12:513-518.
28. Dunn WR, Gardiner SM. No evidence for vascular remodelling during hypertension induced by chronic inhibition of nitric oxide synthase in Brattleboro rats. J Hypertens. 1995;13:849-857.[Medline] [Order article via Infotrieve]
29. Li JS, Schiffrin EL. Resistance artery structure and neuroeffector mechanisms in hypertension induced by inhibition of nitric oxide synthase. Am J Hypertens. 1994;7:996-1004.[Medline] [Order article via Infotrieve]
30. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15:527-537.
31. Lee RMKW, Garfield RE, Forrest JB, Daniel EE. Morphometric study of structural changes in the mesenteric blood vessels of spontaneously hypertensive rats. Blood Vessels. 1983;20:57-71.[Medline] [Order article via Infotrieve]
32.
Korsgaard N, Mulvany MJ. Cellular
hypertrophy in mesenteric resistance vessels from renal
hypertensive rats. Hypertension. 1988;12:162-167.
33. Schiffrin EL. Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. J Hypertens. 1995;13:817-821.[Medline] [Order article via Infotrieve]
34.
Baumbach GL. Effects of increased pulse pressure
on cerebral arterioles. Hypertension. 1996;27:159-167.
35.
Pollock DM, Polakowski JS, Divish BJ, Opgenorth
TJ. Angiotensin blockade reverses hypertension
during long-term nitric oxide synthase inhibition.
Hypertension. 1993;21:660-666.
36.
Jover B, Herizi A, Ventre F, Dupont M, Mimran A.
Sodium and angiotensin in hypertension induced by long-term
nitric oxide blockade. Hypertension. 1993;21:944-948.
37.
Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz
R. Chronic inhibition of nitric oxide synthesis. A new model of
arterial hypertension. Hypertension. 1992;20:298-303.
38.
Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin
EL. Vascular structure and expression of endothelin-1 gene in
L-NAMEtreated spontaneously hypertensive rats.
Hypertension. 1996;27:49-55.
39.
Li JS, Grove K, Deschepper CF, Schiffrin EL.
Comparison of effect of endothelin antagonism and
angiotensin-converting enzyme inhibition on blood pressure
and vascular structure in spontaneously hypertensive rats treated
with N
-nitro-L-arginine
methyl ester. Correlation with topography of vascular endothelin-1 gene
expression. Hypertension. 1996;28:188-195.
40.
Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel
S. Growth factor activity of endothelin on vascular smooth
muscle. Am J Physiol. 1990;258:C408-C415.
41. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.[Medline] [Order article via Infotrieve]
42.
Delacrétaz E, Zanchi A, Nussberger J, Hayoz D,
Aubert JF, Brunner HR, Waeber B. Chronic nitric oxide synthase
inhibition and carotid artery distensibility in renal hypertensive
rats. Hypertension. 1995;26:332-336.
43.
Armstrong ML, Heistad DD, Marcus ML, Megan MB, Piegors
DJ. Structural and hemodynamic responses of
peripheral arteries of macaque monkeys to atherogenic
diet. Arteriosclerosis. 1985;5:336-346.
44. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.[Abstract]
45.
Tagawa H, Tomoike H, Nakamura M. Putative
mechanisms of impairment of endothelium-dependent
relaxation of the aorta with atheromatous plaque in
heritable hyperlipidemic rabbits. Circ
Res. 1991;68:330-337.
This article has been cited by other articles:
![]() |
M. J. Cipolla, J. Smith, N. Bishop, L. V. Bullinger, and J. A. Godfrey Pregnancy Reverses Hypertensive Remodeling of Cerebral Arteries Hypertension, April 1, 2008; 51(4): 1052 - 1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Cipolla Cerebrovascular Function in Pregnancy and Eclampsia Hypertension, July 1, 2007; 50(1): 14 - 24. [Full Text] [PDF] |
||||
![]() |
G. L. Baumbach, S. P. Didion, and F. M. Faraci Hypertrophy of Cerebral Arterioles in Mice Deficient in Expression of the Gene for CuZn Superoxide Dismutase Stroke, July 1, 2006; 37(7): 1850 - 1855. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Cipolla, N. DeLance, and L. Vitullo Pregnancy Prevents Hypertensive Remodeling of Cerebral Arteries: A Potential Role in the Development of Eclampsia Hypertension, March 1, 2006; 47(3): 619 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Baumbach, C. D. Sigmund, and F. M. Faraci Structure of Cerebral Arterioles in Mice Deficient in Expression of the Gene for Endothelial Nitric Oxide Synthase Circ. Res., October 15, 2004; 95(8): 822 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Chillon and G. L. Baumbach Effects of Indapamide, a Thiazide-Like Diuretic, on Structure of Cerebral Arterioles in Hypertensive Rats Hypertension, May 1, 2004; 43(5): 1092 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Baumbach, C. D. Sigmund, and F. M. Faraci Cerebral Arteriolar Structure in Mice Overexpressing Human Renin and Angiotensinogen Hypertension, January 1, 2003; 41(1): 50 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Baumbach, C. D. Sigmund, T. Bottiglieri, and S. R. Lentz Structure of Cerebral Arterioles in Cystathionine {beta}-Synthase-Deficient Mice Circ. Res., November 15, 2002; 91(10): 931 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nasreen, T. Nabika, H. Shibata, H. Moriyama, K. Yamashita, J. Masuda, and S. Kobayashi T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers: Possible Gene-Environmental Interaction Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 605 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Regrigny, F. Dupuis, J. Atkinson, P. Liminana, E. Scalbert, P. Delagrange, and J.-M. Chillon Cerebral arteriolar structure and function in pinealectomized rats Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1476 - H1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Ceiler and J. G. R. De Mey Chronic NG-Nitro-L-Arginine Methyl Ester Treatment Does Not Prevent Flow-Induced Remodeling in Mesenteric Feed Arteries and Arcading Arterioles Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2057 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Regrigny, J. Atkinson, C. Capdeville-Atkinson, P. Liminana, and J.-M. Chillon Effect of Lovastatin on Cerebral Circulation in Spontaneously Hypertensive Rats Hypertension, May 1, 2000; 35(5): 1105 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Chillon and G. L. Baumbach Effects of an Angiotensin-Converting Enzyme Inhibitor and a ß-Blocker on Cerebral Arterioles in Rats Hypertension, March 1, 1999; 33(3): 856 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Moreau, H. Takase, L. V. d'Uscio, T. F. Luscher, and G. L. Baumbach Effect of Chronic Nitric Oxide Deficiency on Angiotensin II–Induced Hypertrophy of Rat Basilar Artery • Editorial Comment Stroke, May 1, 1998; 29(5): 1031 - 1036. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nasreen, T. Nabika, H. Shibata, H. Moriyama, K. Yamashita, J. Masuda, and S. Kobayashi T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers: Possible Gene-Environmental Interaction Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 605 - 610. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |